Tags

Type your tag names separated by a space and hit enter

Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis.
Mol Nutr Food Res 2015; 59(1):147-59MN

Abstract

The red wine polyphenol, resveratrol, is highly effective in treating type 2 diabetes mellitus (T2DM) in animal models, but there is no consensus regarding its efficacy in humans. We conducted a systematic review, which included searches in nine scholarly databases and six clinical trial registries, and identified randomized controlled clinical trials whereby resveratrol was used as an adjunct to pharmaceutical interventions in T2DM. Meta-analysis on clinical parameters was performed for available data. Of 764 articles originally identified, data from six unique datasets, examining a total of 196 T2DM patients (104 resveratrol, 92 control/placebo) ultimately met inclusion criteria. Statistically significant (p < 0.05) positive effects, indicating that resveratrol supplementation was more effective than placebo/control, were identified for systolic blood pressure, hemoglobin A1c, and creatinine, but not for fasting glucose, homeostatic model assessment of insulin resistance, diastolic blood pressure, insulin, triglycerides, LDL, or HDL cholesterol. No major adverse events were reported and side effects of resveratrol were not different than placebo/control. Though limitations in sample size and treatment duration preclude definitive changes in clinical practice, significant improvements in multiple cardiometabolic biomarkers and an excellent safety profile support resveratrol as a leading candidate as an adjunct to pharmacological management of T2DM.

Authors+Show Affiliations

Jacksonville University College of Health Sciences, Jacksonville, FL, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Review
Systematic Review

Language

eng

PubMed ID

25138371

Citation

Hausenblas, Heather A., et al. "Resveratrol Treatment as an Adjunct to Pharmacological Management in Type 2 Diabetes Mellitus--systematic Review and Meta-analysis." Molecular Nutrition & Food Research, vol. 59, no. 1, 2015, pp. 147-59.
Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis. Mol Nutr Food Res. 2015;59(1):147-59.
Hausenblas, H. A., Schoulda, J. A., & Smoliga, J. M. (2015). Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis. Molecular Nutrition & Food Research, 59(1), pp. 147-59. doi:10.1002/mnfr.201400173.
Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol Treatment as an Adjunct to Pharmacological Management in Type 2 Diabetes Mellitus--systematic Review and Meta-analysis. Mol Nutr Food Res. 2015;59(1):147-59. PubMed PMID: 25138371.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis. AU - Hausenblas,Heather A, AU - Schoulda,Jennifer A, AU - Smoliga,James M, Y1 - 2014/10/09/ PY - 2014/03/10/received PY - 2014/07/21/revised PY - 2014/07/29/accepted PY - 2014/8/21/entrez PY - 2014/8/21/pubmed PY - 2015/9/26/medline KW - Cardiometabolic KW - French paradox KW - Nutraceutical KW - SIRT1 KW - Sirtuin SP - 147 EP - 59 JF - Molecular nutrition & food research JO - Mol Nutr Food Res VL - 59 IS - 1 N2 - The red wine polyphenol, resveratrol, is highly effective in treating type 2 diabetes mellitus (T2DM) in animal models, but there is no consensus regarding its efficacy in humans. We conducted a systematic review, which included searches in nine scholarly databases and six clinical trial registries, and identified randomized controlled clinical trials whereby resveratrol was used as an adjunct to pharmaceutical interventions in T2DM. Meta-analysis on clinical parameters was performed for available data. Of 764 articles originally identified, data from six unique datasets, examining a total of 196 T2DM patients (104 resveratrol, 92 control/placebo) ultimately met inclusion criteria. Statistically significant (p < 0.05) positive effects, indicating that resveratrol supplementation was more effective than placebo/control, were identified for systolic blood pressure, hemoglobin A1c, and creatinine, but not for fasting glucose, homeostatic model assessment of insulin resistance, diastolic blood pressure, insulin, triglycerides, LDL, or HDL cholesterol. No major adverse events were reported and side effects of resveratrol were not different than placebo/control. Though limitations in sample size and treatment duration preclude definitive changes in clinical practice, significant improvements in multiple cardiometabolic biomarkers and an excellent safety profile support resveratrol as a leading candidate as an adjunct to pharmacological management of T2DM. SN - 1613-4133 UR - https://www.unboundmedicine.com/medline/citation/25138371/full_citation L2 - https://doi.org/10.1002/mnfr.201400173 DB - PRIME DP - Unbound Medicine ER -